nach oben

Pediatric Nephrology

Erschienen in:

01.11.2004 | Brief Report

Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome

verfasst von: David Raveh, Ovadia Shemesh, Yaakov Jack Ashkenazi, Robert Winkler, Vivian Barak

Erschienen in: Pediatric Nephrology | Ausgabe 11/2004

Einloggen, um Zugang zu erhalten

Abstract

We report a 13-year-old boy with refractory nephrotic syndrome (minimal change with mesangial proliferation) who failed the standard treatment protocols. There was some temporary response to large steroid doses, but even the Mendoza protocol could not induce remission. We show suppression of the proteinuria with Infliximab (Remicade) with tapering of steroids. Serial serum levels of tumor necrosis factor (TNF)-α are shown and discussed. We suggest studying the TNF-α blocking agents as optional treatment for nephrotic syndrome.

Suranyl MG, Guasch A, Hall BM, Myers BD (1993) Elevated levels of TNFα in the nephrotic syndrome in humans. Am J Kidney Dis 22:622

Bakr A, Shokeir M, El-Chenawi F, El-Husseni F, Abdel-rachman A, El-Ashry R (2003) TNFα production from mononuclear cells in nephrotic syndrome. Pediatr Nephrol 18:516–520PubMed

McCarthy ET, Sharma R, Scharma M, Li JZ, Ge XL, Dileezpan KN (1998) TNFα increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9:433–438PubMed

Pai R, Ha H, Kirschenbaum MA, Kamanna VS (1996) Role of tumor necrosis factor alpha on mesangeal cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction. J Am Soc Nephrol 7:914–923PubMed

Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with Etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 343:1044–1045CrossRefPubMed

Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B, Westhovens R (2003) Benefit of anti-TNFα treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 62:368–369CrossRefPubMed

Pusey C (2001) Efficacy of anti-TNFα in the treatment of nephrotoxic nephritis. Symposium on glomerulonephritis and anti-GBM disease: World Congress of Nephrology (ASN), USA (http://www.hdcn.com/symp/01asn/pu/pusey.htm)

Bircan Z, Kara B (2003) Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome. Pediatr Int 45:65–67CrossRefPubMed

Ducloux D, Bresson-Vautrin C, Chalopin J (2001) Use of pentoxifylline in membranous nephropathy. Lancet 357:1672–1673CrossRefPubMed

10.

Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15:463–473CrossRefPubMed

11.

Barak V, Nisman B, Polliack A (1999) The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 62:71–75PubMed

12.

Li Naisan Yu Dondhui (1992) Study on toxicokinetics of crude extract from Tripterygium wilfordii. J Chin Phram Univ 23:25–26

13.

Zhang Xiao Chen Shunle (1993) Effect of Tripterygium wilfordii Hook F on contrasuppressor T cells in SLE nephritic patients. Chin J Immunol 9:230–231

14.

Qiu D, Kao PN (2003) Immunosuppressive and anti-inflammatory mechanisms of Triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. F. Drugs 4:1–18CrossRef

Titel: Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome
verfasst von: David Raveh
Ovadia Shemesh
Yaakov Jack Ashkenazi
Robert Winkler
Vivian Barak
Publikationsdatum: 01.11.2004
Verlag: Springer-Verlag
Erschienen in: Pediatric Nephrology / Ausgabe 11/2004
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-004-1573-2

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome

Abstract

Neu im Fachgebiet Pädiatrie

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2004

Optimising nutrition in chronic renal insufficiency—progression of disease

Reply to the letter from C. von Schnakenburg and M. Krüger

Merit of the cuff-shaving procedure in children with tunnel infection

Reply to the letter from T. Watanabe

Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome

Urinary excretion of calcium and phosphate in preterm infants

Neu im Fachgebiet Pädiatrie

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Update Pädiatrie